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Biolayer interferometry (BLI) is a well-established optical label-free technique to study biomolecular
interactions. Here we describe for the ﬁrst time a cell-based BLI (cBLI) application that allows label-free
real-time monitoring of signal transduction in living cells. Human A431 epidermoid carcinoma cells were
captured onto collagen-coated biosensors and serum-starved, followed by exposure to agonistic com-
pounds targeting various receptors, while recording the cBLI signal. Stimulation of the epidermal growth
factor receptor (EGFR) with EGF, the β2-adrenoceptor with dopamine, or the hepatocyte growth factor
receptor (HGFR/c-MET) with an agonistic antibody resulted in distinct cBLI signal patterns. We show that
the mechanism underlying the observed changes in cBLI signal is mediated by rearrangement of the actin
cytoskeleton, a process referred to as dynamic mass redistribution (DMR). A panel of ligand-binding
blocking and non-blocking anti-EGFR antibodies was used to demonstrate that this novel BLI application
can be efﬁciently used as a label-free cellular assay for compound screening and characterization.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cellular signal transduction upon receptor stimulation is tra-
ditionally measured using classical biochemical assays, for in-
stance by the quantiﬁcation of second messenger molecules or
determination of the phosphorylation status of a protein. How-
ever, a cellular response often involves activation of a complex
network of signaling molecules. By focusing on a single readout
other relevant signaling pathways may be overlooked. In addition,
when screening orphan receptors there often is no knowledge of
which signal transduction route is activated by the receptor. These
challenges can be overcome by measuring an integral cellular re-
sponse, instead of a single pathway. Advantages of such an integral
approach are that no prior knowledge of the signal transduction
cascade is required, and that responses often can be followed in
time which allows evaluation of different signaling dynamics be-
tween compounds. There are commercially available label-free
plate-based approaches that measure an integral outcome of cel-
lular activation. Examples are the xCELLigence (Acea Biosciences)
which measures a change in impedance upon stimulation of ad-
herent cells over time, and the Epic (Corning) and BIND (SRUB.V. This is an open access article u
rritsen).Biosystems) instruments that make use of the optical resonant
waveguide grating technique.
Biolayer interferometry (BLI) is a label-free method that is
commonly used to detect biomolecular interactions. In BLI the
interference pattern of white light reﬂected from two surfaces on a
disposable ﬁber optic-based biosensor is analyzed. The ﬁrst sur-
face on the biosensor tip consists of a layer of immobilized mo-
lecules, and the second surface is an internal reference layer. A
change in the number of molecules bound to the biosensor tip
causes a shift in the interference pattern that can be measured in
real-time (Do et al., 2008). We developed a new BLI application
that is compatible with living cells. Human A431 epidermoid
carcinoma cells were captured on optical biosensors and exposed
to a diverse set of agonistic compounds. This resulted in dose-
dependent and compound-speciﬁc BLI signals. We show that the
observed changes in BLI signal are the consequence of intracellular
signaling affecting actin remodeling. Actin remodeling is thought
to lead to changes in optical density by the redistribution of in-
tracellular mass toward or away from the interface of the cell with
the biosensor, a process referred to as dynamic mass redistribution
(DMR) (Grundmann and Kostenis, 2015). Finally, we show that this
unbiased label-free cell-based technique can easily be applied to
functionally screen a panel of anti-EGFR antibodies for antag-
onistic properties.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Antibodies and compounds
The human antibodies speciﬁc to human EGFR zalutumumab
and monoclonal antibodies (mAbs) 003, 005, 011 and 018 have
been described previously (Bleeker et al., 2004; Dechant et al.,
2008). IgG1-cMET speciﬁc for HGFR/c-MET was generated by im-
munizing HuMab mice (Medarex) with alternating NCI-H441 tu-
mor cells and recombinant His-tagged extracellular domain of
c-MET coupled to keyhole limpet hemocyanin (cMetECDHis-KLH).
Antibody IgG1-cMET and mAbs 003, 005, 011 and 018 carried an
engineered K409R mutation in the CH3 region (Labrijn et al., 2013)
which does not affect binding or functional IgG1 properties. IgG1-
cMET had an additional N297Q mutation (Tao and Morrison, 1989)
which does not affect the antigen binding properties of IgG1-
cMET. Nimotuzumab (Mateo et al., 1997), ICR62 (Modjtahedi et al.,
1993), necitumumab (Lu et al., 2004), mAb 806, and IgG1-cMET
were expressed in Freestyle™ HEK293-F cells (Invitrogen). Matu-
zumab (Murthy et al., 1987) was expressed in Expi293F™ cells
(Gibco). IgG1-b12 directed against the envelope glycoprotein
gp120 of human immunodeﬁciency virus type 1 (Roben et al.,
1994) was expressed in CHOK1SV cells (Lonza). Antibodies were
produced as human IgG1 with a κ light chain, puriﬁed using
protein A afﬁnity chromatography (MabSelectSuRe, GE Healthcare)
and formulated in phosphate-buffered saline (B. Braun). Zalutu-
mumab was produced by Lonza. Cetuximab (Erbitux) (Berger et al.,
2011), panitumumab (Vectibix) (Yang et al., 1999) and trastuzumab
(Herceptin) (Carter et al., 1992) were from Merck, Amgen and
Roche respectively. Mouse anti-human EGFR IgG2a 528 (Kawa-
moto et al., 1983) was purchased from Calbiochem. Generation of
the bispeciﬁc DuoBody molecule BsAb-cMETxb12 from the par-
ental antibodies IgG1-cMET-F405L and IgG1-b12-K409R was per-
formed as previously described (Labrijn et al., 2014), using an 1.3-
fold excess of IgG1-b12-K409R in order to minimize the amount of
residual agonistic IgG1-cMET-F405L homodimer in the DuoBody
batch. The residual amount of IgG1-cMET-F405L homodimer was
0.3% as determined by cation exchange chromatography. Epi-
dermal Growth Factor (EGF) and dopamine hydrochloride were
obtained from Sigma-Aldrich.
2.2. Cell culture and capture of cells to biosensors
Amine-reactive second-generation biosensors (ForteBio) were
incubated for 2 h at room temperature with a solution (0.1–1.0 mg/
ml) of Collagen I, high concentration from rat tail (Corning) in
water (B. Braun) followed by air-drying for at least 2 h. Human
A431 cells (Deutsche Sammlung von Mikroorganismen und
Zellkulturen) were cultured in RPMI 1640 (Lonza) containing 10%
heat-inactivated donor bovine serum with iron, New Zealand
origin (Gibco), penicillin (50 U/ml) and streptomycin (50 U/ml)
(Lonza). Cells were harvested using Trypsin-EDTA (Lonza), washed
with culture medium, and resuspended in undiluted 2 Happy
Cell RPMI Advanced Suspension Medium (Biocroi) to 10106
cells/ml. 40 ml/well cell suspension was transferred to a 384 tilted-
well plate (ForteBio). The collagen-coated biosensors were pre-wet
for 10 min using 100 ml RPMI 1640 supplemented with penicillin
and streptomycin in a 96 well half-area plate (Greiner Bio-One)
inside an Octet HTX instrument (ForteBio), while the 384 tilted
well plate was incubated at 30 °C at a shaker speed of 300 rpm.
Capture of the cells to collagen-coated biosensors was then per-
formed for 2000 s at 30 °C and a shaker speed of 300 rpm.
After capture of the cells the biosensors were transferred to
serum-starvation medium (RPMI 1640 containing 0.1% serum,
penicillin and streptomycin) and incubated overnight for at least
20 h in a cell culture incubator.2.3. Cell-based biolayer interferometry
After overnight serum-starvation the collagen-coated bio-
sensors containing cells were placed into the Octet HTX. Sample
solutions containing compounds with or without inhibitors were
prepared in serum-starvation medium in 384 tilted-well plates.
After 10 min incubation of the sample plate at 30 °C with 300 rpm
shaking, biosensors were dipped into serum-starvation medium
with or without inhibitors for 1000 s in order to equilibrate. Next,
the biosensors were dipped into sample solutions for 2000 s at
30 °C with 300 rpm shaking.
When indicated, the biosensors containing A431 cells were
ﬁxed with 3.7% formaldehyde (Sigma-Aldrich) in PBS for 15 min at
room temperature. When indicated, the collagen-coated bio-
sensors containing A431 cells were pretreated for 2 h in a cell
culture incubator with serum-starvation medium containing the
EGFR inhibitor tyrphostin AG-1478 (1 mM, Tocris), the β2-adreno-
ceptor antagonist propranolol (1 mM, Tocris), the actin inhibitor
cytochalasin B (10 mM, Sigma-Aldrich) or antibodies (15 mg/ml,
100 nM). Whenever inhibitors from DMSO stocks were used, the
total amount of DMSO (Sigma-Aldrich) in the serum-starvation
medium was kept constant at 0.05%, including solutions used for
pretreatment, baseline and controls. The data traces shown in the
graphs were obtained after subtraction of reference sensors ex-
posed to serum-starvation medium with or without the appro-
priate inhibitors, using Data Analysis software v8.1 (ForteBio). The
processed data were plotted using Prism 6 (Graphpad Software).
2.4. Cell viability
After cell capture using collagen-coated or untreated control
biosensors, biosensors were incubated overnight in a cell culture
incubator in serum-starvation medium containing 10% AlamarBlue
(Invitrogen). The next day, ﬂuorescence (excitation 515 nm, emis-
sion 615 nm) was determined using an EnVision Multilabel Reader
(PerkinElmer). The two groups were compared with the Welch-
corrected t-test using Prism 6.
2.5. Biosensor images
Images of the tip of the biosensor were taken while the bio-
sensor was kept vertically above a 96 well half-area plate with the
biosensor tip submerged in medium, using a Zeiss Axiovert 40 C
inverted microscope in combination with a Canon G10 PowerShot
digital camera.3. Results
3.1. Capture of living cells to biosensors
In a typical biolayer interferometry (BLI) experiment using the
Octet HTX platform, biosensors coated with a biocompatible ma-
trix are used to interrogate 96- or 384-well plates by dipping the
biosensors in the sample solution. This design implies that when
adherent cells are to be captured from a cell suspension to the
biosensor surface, the cells need to adhere to the bottom of the
biosensor. Therefore the biosensors need to be coated with an
agent that allows fast and ﬁrm attachment of living cells. To this
end, the biosensors were coated with the extracellular matrix
protein collagen type I.
The adherent human epidermoid carcinoma cell line A431 was
suspended in 2 Happy Cell Advanced Suspension Medium. The
composition of Happy Cell Advanced Suspension Medium is de-
signed to keep cells ﬂoating in suspension and was originally de-
veloped for 3D culture of cells. This property was exploited to
Fig. 1. Capture and viability of A431 cells. (A) Collagen-coated (black) or non-coated control (grey) biosensors were dipped in a suspension of cells and the BLI signal was
recorded for 2000 s. The average signal including standard deviation (grey shading) of 92 collagen-coated biosensors and 4 non-coated biosensors from a representative
experiment is shown. Pictures of a collagen-coated (B) and non-coated control (C) biosensor tip were taken directly after the cell capture experiment. The diameter of a
biosensor tip is 0.6 mm. (D) A collagen-coated biosensor tip was incubated overnight under low serum conditions and a picture was taken the next day. (E) Viability of A431
cells captured on 4 collagen-coated biosensors after overnight serum-starvation was determined using AlamarBlue and compared with 4 non-coated biosensors or wells
containing no biosensors (dashed line). Representative experiments are shown.
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allowing cell adhesion onto the biosensors.
During incubation of the biosensors with the cell suspension, a
reproducible BLI signal was recorded (Fig. 1A). Capture of cells onFig. 2. Agonist-induced cell-based biolayer interferometry. (A) A431 cells were exp
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Fig. D (D) The dopamine-induced cBLI signal at 350 s was plotted against the dopam
standard deviation. (E and F) Cells were exposed to the following concentrations of IgG1
(red); 3.0 mg/ml (orange); 1.0 mg/ml (dark green); 0.3 mg/ml (light green); 100 ng/ml (bl
sensors. The dotted line at 400 s indicates the data points used for G. Schematic represe
molecule BsAb-cMETxb12 (green and blue) are shown in E and F respectively. (G) IgG1-c
Each data point represents the average of two duplicates with standard deviation. Eac
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D. Verzijl et al. / Biosensors and Bioelectronics 87 (2017) 388–395 391particles to the optical biosensors can result in a negative nm shift
rather than a positive nm shift.
Brightﬁeld imaging of the biosensors directly after cell capturerevealed that cells adhered only to the biosensor surface after
collagen-coating (Fig. 1B) but not to non-coated sensors (Fig. 1C).
After overnight incubation in serum-starvation medium the cells
Fig. 3. Inhibition of receptor activation abrogates cBLI signal. (A) A431 cells were pretreated for 2 h with the EGFR tyrosine kinase inhibitor AG-1478 (1 mM, blue traces) or
control medium (red traces) and the cBLI signal induced by EGF (100 nM) was determined. (B) Cells were pretreated for 2 h with the β2-adrenoceptor antagonist propranolol
(1 mM, blue traces) or control medium (red traces) and the cBLI signal induced by dopamine (100 mM) was determined. Each graph shows data from a representative
experiment performed with duplicate biosensors, and each experiment was repeated three times.
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The viability of cells on collagen-coated biosensors was ad-
dressed by an AlamarBlue cell viability assay. A signiﬁcant increase
in ﬂuorescent AlamarBlue signal was observed for the collagen-
coated biosensors with cells, versus non-coated control biosensors
yielding only background signal intensity (P value o0.0001,
Fig. 1E). This shows that A431 cells on collagen-coated biosensors
are viable after capture and 24 h serum-starvation.
3.2. Agonist-induced cell-based biolayer interferometry
A431 cells express high levels of the epidermal growth factor
receptor (EGFR) (Fang et al., 2005). EGFR is a single transmem-
brane receptor tyrosine kinase which is activated upon binding of
its ligand EGF. EGF is a soluble protein with a molecular weight of
approximately 6 kDa, which induces cellular proliferation, differ-
entiation, and survival through EGFR.
A431 cells captured on collagen-coated biosensors were ex-
posed to different concentrations of EGF while recording the cell-
based BLI (cBLI) signal. A time- and dose-dependent positive cBLI
signal was obtained (Fig. 2A). The cBLI signal reached a maximum
after approximately 1000 s. When the signal at 1000 s was plotted
against the EGF concentration, a dose-response relationship was
observed with an average EC50 value of 2.271.8 nM (Fig. 2B).
A431 cells also endogenously express the β2-adrenoceptor, a
member of the G protein-coupled receptor (GPCR) family (Fang
and Ferrie, 2008). The β2-adrenoceptor is activated by low mole-
cular weight compounds such as adrenaline and dopamine. Ex-
posure of cells captured on collagen-coated biosensors to dopa-
mine (molecular weight 153 Da) resulted in a cBLI signal distinct
from the one observed for EGF exposure. The dopamine-induced
cBLI signal consisted of two phases (Fig. 2C): a positive signal
which peaked after approximately 350 s, followed by a negative
signal. When the cBLI signal at 350 s was plotted against the
concentration of dopamine, an average EC50 of 2.372.1 mM was
observed (Fig. 2D).
The hepatocyte growth factor receptor (HGFR), also called
c-MET, is another receptor tyrosine kinase that is expressed on
A431 cells. c-MET is essential in wound healing, embryonic de-
velopment and organogenesis, and plays an important role in the
development of many human cancers. Inhibition of the interaction
between c-MET and its ligand HGF, for example with monoclonal
antibodies, may be of therapeutic value. However, many bivalent
antibodies directed against c-MET have unwanted intrinsic ago-
nistic activity because they induce homodimerization by cross-
linking two c-MET receptors, which results in self-activation ofc-MET (Prat et al., 1998). We studied the effect of the bivalent
antibody IgG1-cMET on A431 cells that were captured on collagen-
coated biosensors. IgG1-cMET (molecular weight approximately
150 kDa) dose-dependently induced a negative cBLI signal which
reached a minimum around 400 s (Fig. 2E). The shape of the cBLI
signal observed with IgG1-cMET was distinct from the signals
obtained with EGF or dopamine and was speciﬁc to IgG1-cMET, as
no signiﬁcant changes in the cBLI signal were observed in the
presence of the negative control antibody IgG1-b12. IgG1-b12 is
directed against a target that is not expressed on A431 cells, i.e. the
human immunodeﬁciency virus-1 envelope protein gp120.
In order to further evidence the speciﬁcity of the cBLI signal
towards antibody-induced homodimerization of c-MET, we tested
a bispeciﬁc functionally monovalent version of IgG1-cMET, based
on the DuoBodys format (Labrijn et al., 2014). The bispeciﬁc an-
tibody was constructed with one Fab-arm from IgG1-cMET while
the other Fab-arm was from the negative control antibody IgG1-
b12. The resulting bispeciﬁc antibody, designated BsAb-cMETxb12,
is functionally monovalent and thus unable to cross-link two
c-MET receptors. Exposure of A431 cells to functionally mono-
valent BsAb-cMETxb12 signiﬁcantly reduced the observed cBLI
signal (Fig. 2F). This suggests that the parental bivalent IgG-cMET
antibody indeed induces a cBLI signal by cross-linking and
homodimerization of c-MET. At the highest concentrations tested
(10–100 mg/ml) we observed a minimal residual cBLI signal to
functionally monovalent BsAb-cMETxb12. We speculate that these
small cBLI signals are due to the presence of trace amounts (0.3%)
of bivalent IgG1-cMET in the BsAb-cMETxb12 DuoBody
preparation.
The cBLI signals induced by the bivalent IgG1-cMET at 400 s
were plotted against the antibody concentration. An average EC50
of 9.470.4 nM, corresponding to approximately 1.5 mg/ml, was
obtained for IgG1-cMET (Fig. 2F).
3.3. Inhibition of receptor activation abrogates cBLI signal
We hypothesized that the observed cBLI signals were the result
of agonist-induced intracellular signaling and not a direct binding
event of the compounds to their cognate receptors. In order to test
this hypothesis, A431 cells were pretreated with the EGFR tyrosine
kinase inhibitor tyrphostin AG-1478. AG-1478 effectively in-
activates the kinase domain of EGFR and thereby inhibits EGFR-
mediated signaling. Treatment of cells with AG-1478 completely
inhibited the cBLI signals induced by EGF (Fig. 3A). This indicates
that EGFR-mediated signal transduction causes the EGF-induced
cBLI signal.
Fig. 4. Dynamic Mass Redistribution as mechanism of action. A431 cells were ﬁxed with formaldehyde (green traces) or pretreated for 2 h with control medium (red
traces) or the actin polymerization inhibitor cytochalasin B (10 mM, blue traces) and the cBLI signal induced by (A) EGF (100 nM), (B) dopamine (100 mM) or (C) IgG1-cMET
(10 mg/ml, 67 nM) was determined. Each graph shows data from a representative experiment performed with duplicate biosensors which was repeated three times.
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mine-mediated cBLI signal was tested. A431 cells were pre-in-
cubated with the β2-adrenoceptor antagonist propranolol and the
dopamine response was determined in the presence of propra-
nolol. The β2-adrenoceptor-mediated cBLI signal induced by the
agonist dopamine was completely inhibited by the antagonist
propranolol (Fig. 3B). Together, these data indicate that agonist-
mediated signal transduction is important in cBLI.
3.4. Dynamic mass redistribution underlies cBLI signal
In established optical label-free cell-based techniques such as
resonant waveguide grating, intracellular dynamic mass redis-
tribution (DMR) has been proposed to underlie the observed shifts
in reﬂected wavelength (Grundmann and Kostenis, 2015). Stimu-
lation of a cell frequently induces actin remodeling. This results in
a change in optical density at the biosensor-cell interface through
redistribution of intracellular mass towards or away from the
biosensor surface. The actin cytoskeleton plays an important role
in this process (Grundmann and Kostenis, 2015). We tested this
hypothesis by interfering with actin remodeling by either chemical
ﬁxation or inhibiting actin polymerization with the low molecular
weight compound cytochalasin B. In the ﬁrst approach, A431 cells
were captured on collagen-coated biosensors and ﬁxed with for-
maldehyde. Formaldehyde ﬁxation randomly cross-links cellular
proteins and therefore prevents morphological rearrangements.
Fixation of the cells prior to stimulation with EGF completely ab-
rogated the EGFR-mediated cBLI signal (Fig. 4A). Likewise, when
cells were ﬁxed with formaldehyde both the dopamine-induced
response through the β2-adrenoceptor (Fig. 4B) as well as the
c-MET-mediated cBLI signal induced by the IgG1-cMET antibody(Fig. 4C) were fully abolished. To further strengthen our ﬁnding
that actin remodeling causes cBLI we treated cells with the actin
polymerization inhibitor cytochalasin B. Pretreatment of cells with
cytochalasin B inhibited the cBLI signals induced by EGF (Fig. 4A),
dopamine (Fig. 4B), and the antibody IgG1-cMET (Fig. 4C). To-
gether, these data strongly indicate that the cBLI signals obtained
with these agonistic molecules are due to a signaling cascade that
leads to DMR and morphological rearrangements.
3.5. Screening for antibodies that inhibit EGFR activation
We next investigated whether the cBLI technique may have
applications in antibody discovery screening campaigns. Having
shown that the EGFR tyrosine kinase inhibitor AG-1478 completely
abolishes cBLI signals on cells exposed to EGF, we postulated that
also antibodies that block the binding of EGF to EGFR or inhibit
EGFR signaling could be identiﬁed by cBLI. To test this, serum-
starved A431 cells on collagen-coated biosensors were incubated
for 2 h with 100 nM of the EGF-blocking antibody cetuximab
(Berger et al., 2011) or mAb 011 which has been reported to par-
tially block EGF binding (Dechant et al., 2008). Subsequently, the
cBLI signal induced by EGF (100 nM) was determined in the pre-
sence or absence of these antibodies. Cetuximab completely in-
hibited the EGF response, while incubation with mAb 011 resulted
in partial inhibition (Fig. 5A). Incubation of cells with cetuximab or
mAb 011 alone had no effect (data not shown). This result de-
monstrates that cBLI can help to discriminate between the ago-
nist-blocking properties of antibodies.
We applied this setup to a panel of antibodies directed against
EGFR to screen for their ability to inhibit EGF-induced signaling.
Incubation of A431 cells with anti-EGFR antibodies in the absence
Fig. 5. Inhibition of EGF response by anti-EGFR antibodies. A431 cells were pretreated for 2 h with antibody (15 mg/ml, 100 nM) and the cBLI signal induced by EGF
(100 nM) in the presence of antibody (100 nM) was recorded. (A) The traces represent the average with standard deviation of 4 biosensors treated with EGF only (red trace),
2 biosensors treated with cetuximab þ EGF (green trace) and 2 biosensors incubated with mAb 011þ EGF (blue trace). The dotted line indicates the 1000 s time point used
for the data in Fig. B. Data from a representative experiment is shown that was repeated three times. (B) The normalized EGF (100 nM) response at 1000 s in the presence of
indicated antibodies (15 mg/ml, 100 nM) is shown. The EGF response in the presence of the negative control antibody IgG1-b12 was set as 100% and was comparable to the
EGF response in the absence of antibody (medium only). The average data including standard deviation from three independent experiments performed with duplicate
biosensors per antibody is shown.
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previously described ligand-blocking properties such as cetuximab
(Berger et al., 2011), zalutumumab (Bleeker et al., 2004; Dechant
et al., 2008), panitumumab (Dechant et al., 2008; Yang et al., 1999),
ICR62 (Modjtahedi et al., 1993) and necitumumab (Lu et al., 2004)
completely blocked the EGF response as recorded by the cBLI
signal after 1000 s (Fig. 5B). The antibodies 528 (Kawamoto et al.,
1983), matuzumab (Murthy et al., 1987), mAbs 003, 005 and 011
(Dechant et al., 2008) showed partial inhibition of the EGF re-
sponse. Although matuzumab was reported to block EGF binding
to EGFR (Murthy et al., 1987), its inhibition of the EGF response
was relatively modest. This may be explained by the fact that
matuzumab does not directly block access of EGF to its binding site
on EGFR like cetuximab, but rather non-competitively and steri-
cally blocks the EGFR domain-rearrangement required for high-
afﬁnity ligand binding and receptor dimerization (Schmiedel et al.,
2008). As expected, mAb 018 which does not block EGF binding to
EGFR (Dechant et al., 2008) and the negative control antibody
trastuzumab directed against the related HER2 receptor did not
inhibit the EGF-mediated cBLI signal. Similarly, mAb 806, which
preferentially recognizes an EGFR variant expressed on tumor cells
(Johns et al., 2002), did not block the EGF response. Also nimotu-
zumab was unable to block the EGF response at the used con-
centration, although it has been reported as a ligand-blocking
antibody (Mateo et al., 1997). Indeed, in previous studies it was
shown that 10- to 20-fold higher concentrations of nimotuzumab
are needed to achieve full EGFR signaling blockage when com-
pared to cetuximab, likely due to its lower afﬁnity for EGFR (Berger
et al., 2011). The results obtained with this comprehensive anti-
EGFR panel indicate that this novel label-free assay technique can
be successfully applied to screening for ligand-inhibiting proper-
ties of antibodies.4. Discussion
In this report we show for the ﬁrst time the applicability of
biolayer interferometry (BLI) to detect changes in living cells in
response to drug treatment. The BLI signals that we obtained
during the capture of A431 cells to collagen-coated biosensors
(Fig. 1A) are most likely the result of direct binding of the cell to
the biosensor, resulting in an increase in thickness on thebiosensor surface. In contrast, the cell-based BLI (cBLI) signals
obtained by stimulation of cells with agonists are the result of
intracellular signaling leading to dynamic mass redistribution
(DMR), rather than direct binding of the agonist to the cell.
It is likely that the large size of the A431 cells prevents the
detection of direct binding of compounds to the cell, which needs
to take place close to the biosensor surface in order to result in a
BLI signal. This is for instance exempliﬁed by the experiment
where the EGF-mediated cBLI signal is completely blocked with
the EGFR tyrosine kinase inhibitor AG-1478 (Fig. 3A). When
binding of EGF to EGFR expressed on the A431 cells would con-
tribute to the observed cBLI signal, the direct binding of EGF
(6 kDa) to the cells would still be recorded even though signaling
is inhibited by AG-1478. Similarly, the direct binding of proteins
such as EGF or the IgG1-cMET antibody (150 kDa) to for-
maldehyde-ﬁxed or cytochalasin B-treated cells should result in a
BLI signal when direct binding events are contributing to the cBLI
signal (Fig. 4A and C).
Besides the use of collagen-coated biosensors to capture A431
cells, we have used lectins to capture cells during assay develop-
ment. Lectins are proteins that bind to the sugar moieties of gly-
coproteins that are expressed on the cell membrane. We suc-
cessfully used the lectins concanavalin A and wheat germ agglu-
tinin to capture A431 cells, human AU565 breast carcinoma cells
and the human B lymphocyte suspension cell line Raji to bio-
sensors (Supplementary Fig. S1A-H). In addition, cells have been
captured using biosensors coated with antibodies directed against
cell surface-expressed targets (Supplementary Fig. S1I-K). We
decided to continue our studies with collagen as a generic capture
method because collagen-coating of biosensors resulted in a
proper adherent morphology of the A431 cells (Fig. 1D) that con-
tributes to an efﬁcient interaction of the cells with the biosensor
surface, which is needed for a DMR signal.
cBLI can be used to study a variety of extracellular stimuli that
result in DMR without prior knowledge of the intracellular signal
transduction pathways that are involved, both for agonist and
antagonist characterization. Structurally and functionally diverse
agonists such as the growth factor EGF, the low molecular weight
agonist dopamine and a c-MET antibody elicited speciﬁc and
characteristic cBLI signatures (Fig. 2). This suggests that cBLI can
differentiate between different kinds of activation mechanisms.
We have even noticed subtle differences in the cBLI ﬁngerprint of
D. Verzijl et al. / Biosensors and Bioelectronics 87 (2017) 388–395 395dopamine and structurally related analogs such as pindolol, al-
prenolol and tyramine, suggestive of ligand-directed functional
selectivity (data not shown). Similar observations between dopa-
mine and its analogs have been made by others using resonant
waveguide grating (RWG), an established label-free cell-based
optical biosensor technique (Fang and Ferrie, 2008). The EC50 for
dopamine determined here using cBLI (2.3 mM) was very close to
the EC50 generated with RWG (1.1 mM) (Fang and Ferrie, 2008).
Also the EC50 value for EGF stimulation obtained with cBLI
(2.2 nM) correlates very well with a study in A431 cells using RWG
(Kd of 1.45 nM) (Fang et al., 2005). This implies that the integral
cellular response obtained using cBLI relates well with other hol-
istic approaches.
The inhibitor cytochalasin B was used in order to show that
actin is involved in agonist-induced cBLI signals. Cytochalasin B
only partially inhibited the response induced by EGF (Fig. 4A). This
suggests that besides rearrangement of the actin cytoskeleton,
there may be additional mechanisms involved that lead to DMR or
morphological changes, resulting in a cBLI signal. We speculate
that cBLI may not be limited to actin-mediated DMR responses,
but may be useful in detecting other cellular changes as well, in-
cluding for instance cell detachment, cell death, cell-cell interac-
tions, membrane blebbing or degranulation.
A diverse panel of anti-EGFR antibodies was successfully
screened in order to demonstrate the suitability of cBLI assay in
drug screening campaigns. Moreover, the results obtained with
the low molecular weight antagonist propranolol and the agonist
dopamine show that such a screening is not limited to antibodies
(Fig. 3B).
Summarizing, we have developed a label-free, real-time, cell-
based assay that we named cell-based biolayer interferometry
(cBLI), which can be applied in drug screening campaigns. This
novel assay shows that BLI is a versatile technique that besides its
well established use for detection of biomolecular interactions can
be used to detect effects of agonistic compounds on living cells.Declaration of interest
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